Avalyn Pharma Inc.
AVLN
Positions held
Your positionsAVLN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Avalyn Pharma Inc. operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- The company's market capitalization stands at approximately $1.13 billion, indicating a solid presence in the market.
- Despite recent challenges, Avalyn has a strong buy recommendation with a target mean price of $61.8.
- Avalyn Pharma is currently facing significant financial challenges, with a net income of -28.935 million in Q2 2026.
- The company has reported zero revenue for multiple quarters, highlighting its struggle to generate income.
- Avalyn's financial score indicates a 'Strong Sell' signal with a score of -16.00, reflecting negative market sentiment.
Fundamentals
| Market cap | $1.14B | Enterprise value | $804.93M | Trailing P/E | — | Forward P/E | -13.54 |
| PEG | — | Price / book | 2.86 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.04 |
| Current ratio | 33.12 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $61.80 |
| 52w high | $40.17 | 52w low | $24.14 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$28.9M | -$26.9M | -$20.2M | -$17.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$31.3M | -$27.9M | -$21.8M | -$18.7M |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$85.2M | -$49.7M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$91.3M | -$57.1M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
2026-09-21 · Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
2026-09-16 · Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
2026-09-08 · Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-24 · Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
2026-08-12 · Avalyn Pharma's Q2 Net Loss Widens
2026-08-12 · Avalyn: Q2 Earnings Snapshot
2026-08-12 · Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-13 · What It Means To Hold Moderna Stock In A Crash
Price (daily)
Full chart · RSI · MACD · patterns